AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35149167 — intervention group
Group type: EXPERIMENTAL
Intervention: Dehydrated amnion dressing
Number of subjects: 243
Study 33622590 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent vaccine containing nine serogroups (A, B, C, D, E, F, G, H, I)
Number of subjects: 0
Study 33622590 — intervention group
Group type: COMPARATOR
Intervention: Sequential bivalent vaccines
Number of subjects: 0
Study 33622590 — intervention group
Group type: COMPARATOR
Intervention: Monthly foot-bathing
Number of subjects: 0
Study 33622590 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivalent vaccines containing six serogroups (A, B, C, G, H, I)
Number of subjects: 0
Study 33622590 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-month inter-vaccination interval for bivalent vaccines
Number of subjects: 0
Study 33622590 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-month inter-vaccination interval for bivalent vaccines
Number of subjects: 0
Study 32279529 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (Olmesartan), duration 1 year
Number of subjects: 0
Study 35615840 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modeling technique (mother as model)
Number of subjects: 138
Study 35615840 — intervention group
Group type: COMPARATOR
Intervention: Tell-Show-Do technique
Number of subjects: 138
Study 35615840 — intervention group
Group type: EXPERIMENTAL
Intervention: Live modeling technique (father as model)
Number of subjects: 138
Study 35615840 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen saturation
Number of subjects: 138
Study 32599106 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Endarterectomy (CEA)
Number of subjects: 18997
Study 32599106 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid Stenting (CAS)
Number of subjects: 18997
Study 35482647 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol BMI plus behavioral economic substance-free activity session (BMI + SFAS)
Number of subjects: 66
Study 35482647 — intervention group
Group type: COMPARATOR
Intervention: Education
Number of subjects: 66
Study 32769524 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Tranexamic Acid (10%) with microneedling
Number of subjects: 40
Study 32769524 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (Control)
Number of subjects: 40
Study 33953123 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone + disulfiram (250 mg/day)
Number of subjects: 70
Study 33953123 — intervention group
Group type: COMPARATOR
Intervention: Methadone + placebo
Number of subjects: 70
Study 33039992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ductal lavage and breast massage
Number of subjects: 140
Study 33039992 — intervention group
Group type: COMPARATOR
Intervention: Oral corticosteroids (meprednisone or prednisone for 6 months)
Number of subjects: 140
Study 35659776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Extend intervention (6 weeks of using a Fitbit, weekly digital content, and weekly coaching)
Number of subjects: 14
Study 35659776 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy living information)
Number of subjects: 14
Study 35659776 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-Extend intervention
Number of subjects: 14
Study 35659776 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 14
Study 32233959 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACYW-TT
Number of subjects: 188
Study 32233959 — intervention group
Group type: COMPARATOR
Intervention: MCV4-TT
Number of subjects: 188
Study 35085152 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive intervention
Number of subjects: 0
Study 32949986 — intervention group
Group type: EXPERIMENTAL
Intervention: Early intervention arm of the IMPACT-AFib trial (98,903 patients)
Number of subjects: 197806
Study 32949986 — intervention group
Group type: COMPARATOR
Intervention: Patients with evidence of OAC use in the prior 12 months
Number of subjects: 197806
Study 35037278 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose topiramate (up to 250 mg/day)
Number of subjects: 101
Study 35037278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose topiramate (up to 125 mg/day)
Number of subjects: 101
Study 35037278 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous positive HPV test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous positive co-test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous negative HPV test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous negative co-test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous HPV16-positive test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous HPV16-negative/HPVother-positive test
Number of subjects: 18448
Study 36306283 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-negative women with previous abnormal cytology
Number of subjects: 18448
Study 36306283 — intervention group
Group type: COMPARATOR
Intervention: HPV-negative women
Number of subjects: 18448
Study 32483059 — intervention group
Group type: EXPERIMENTAL
Intervention: Active exergames training (Wii Fit Plus) for 4 weeks, 2 sessions per week
Number of subjects: 72
Study 32483059 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 72
Study 33663418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition and reproductive health education (2 hours every 2 weeks for 3 months)
Number of subjects: 194
Study 33663418 — intervention group
Group type: COMPARATOR
Intervention: Regular health care services (control group)
Number of subjects: 194
Study 34029555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-energy ESWT (HS) group (energy flux density of 0.01 mJ/mm2, 5.8 bar, 1500 impulses, once per week for 4 weeks)
Number of subjects: 60
Study 34029555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy ESWT (LS) group (energy flux density of 0.006 mJ/mm2, 3 bar, 1500 impulses, once per week for 4 weeks)
Number of subjects: 60
Study 34029555 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 60
Study 32603212 — intervention group
Group type: EXPERIMENTAL
Intervention: iArmS robotic armrest
Number of subjects: 18
Study 32603212 — intervention group
Group type: COMPARATOR
Intervention: No iArmS
Number of subjects: 18
Study 35388113 — intervention group
Group type: EXPERIMENTAL
Intervention: Early endoscopy (EE)
Number of subjects: 43
Study 35388113 — intervention group
Group type: COMPARATOR
Intervention: Non-EE (control)
Number of subjects: 43
Study 34309427 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold nanosecond laser (SNL) treatment
Number of subjects: 0
Study 32628688 — intervention group
Group type: EXPERIMENTAL
Intervention: PATHway intervention (eHealth cardiac rehabilitation)
Number of subjects: 60
Study 34657043 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 242
Study 34657043 — intervention group
Group type: COMPARATOR
Intervention: Usual care only (CON)
Number of subjects: 242
Study 33139269 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up colonoscopy at 1 and 3 years (2-examination group)
Number of subjects: 3926
Study 33139269 — intervention group
Group type: COMPARATOR
Intervention: Follow-up colonoscopy at 3 years only (1-examination group)
Number of subjects: 3926
Study 36482065 — intervention group
Group type: EXPERIMENTAL
Intervention: BREATHE intervention with educational sessions and 24 months of follow-up
Number of subjects: 108
Study 36482065 — intervention group
Group type: COMPARATOR
Intervention: Control group continued usual care
Number of subjects: 108
Study 34098827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib
Number of subjects: 3
Study 34098827 — intervention group
Group type: COMPARATOR
Intervention: Abemaciclib
Number of subjects: 3
Study 34098827 — intervention group
Group type: COMPARATOR
Intervention: Palbociclib
Number of subjects: 3
Study 32650760 — intervention group
Group type: EXPERIMENTAL
Intervention: CRSCE-based de-escalation training program
Number of subjects: 0
Study 32650760 — intervention group
Group type: COMPARATOR
Intervention: Routine WPV management training
Number of subjects: 0
Study 32066146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (≤20 mg/wk)
Number of subjects: 4786
Study 32066146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4786
Study 33954799 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision (surgical method)
Number of subjects: 584
Study 33954799 — intervention group
Group type: EXPERIMENTAL
Intervention: Histopathological regression
Number of subjects: 584
Study 33050671 — intervention group
Group type: EXPERIMENTAL
Intervention: randori training
Number of subjects: 61
Study 33050671 — intervention group
Group type: EXPERIMENTAL
Intervention: uchi‐komi training
Number of subjects: 61
Study 33050671 — intervention group
Group type: EXPERIMENTAL
Intervention: running training
Number of subjects: 61
Study 33050671 — intervention group
Group type: COMPARATOR
Intervention: regular training (control)
Number of subjects: 61
Study 35254665 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical prostatectomy (RARP)
Number of subjects: 782
Study 35254665 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical prostatectomy (LRP)
Number of subjects: 782
Study 35254665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RARP and LRP
Number of subjects: 782
Study 35761310 — intervention group
Group type: EXPERIMENTAL
Intervention: PTQ2 intervention (smoking cessation and alcohol abstinence intervention)
Number of subjects: 40
Study 34584971 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 L PEG+Asc
Number of subjects: 164
Study 34584971 — intervention group
Group type: COMPARATOR
Intervention: PEG+SPMC
Number of subjects: 164
Study 32197765 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzoyl peroxide (BPO) applied 5 times
Number of subjects: 30
Study 32197765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 34974493 — intervention group
Group type: EXPERIMENTAL
Intervention: 2/3 circumference, 1.5 cm wide mucosal resection of the gastric cardia (Group A)
Number of subjects: 32
Study 34974493 — intervention group
Group type: COMPARATOR
Intervention: 1/2 circumference, 1.5 cm wide mucosal resection of the gastric cardia (Group B)
Number of subjects: 32
Study 32086190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranial ultrasound (CUS) images with a novel fully-automatic method for ventricle quantification and PHH outcome prediction
Number of subjects: 0
Study 35848920 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised anaesthesia (QuickSleeper)
Number of subjects: 100
Study 35848920 — intervention group
Group type: COMPARATOR
Intervention: Traditional syringe anaesthesia
Number of subjects: 100
Study 32962934 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous remifentanil infusion (R)
Number of subjects: 116
Study 32962934 — intervention group
Group type: COMPARATOR
Intervention: Intermittent fentanyl boluses (F)
Number of subjects: 116
Study 32819467 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model using signal-processed ECG, traditional ECG, and clinical features
Number of subjects: 1202
Study 32819467 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine-learning model
Number of subjects: 1202
Study 33888536 — intervention group
Group type: EXPERIMENTAL
Intervention: Sit Less, Interact, Move More intervention
Number of subjects: 106
Study 33888536 — intervention group
Group type: COMPARATOR
Intervention: Control group (national physical activity recommendations)
Number of subjects: 106
Study 33888536 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effects between groups
Number of subjects: 106
Study 33337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vida Sana intervention (culturally adapted lifestyle intervention with family-based orientation and 22 group sessions over 12 months, plus monthly emails for an additional 12 months)
Number of subjects: 191
Study 33337491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 191
Study 33337491 — intervention group
Group type: EXPERIMENTAL
Intervention: Vida Sana intervention
Number of subjects: 191
Study 34425776 — intervention group
Group type: EXPERIMENTAL
Intervention: SOX+B-mab
Number of subjects: 45
Study 34425776 — intervention group
Group type: COMPARATOR
Intervention: SOX+C-mab
Number of subjects: 45
Study 32588891 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the PTSD Clinicians Exchange website (intervention group)
Number of subjects: 605
Study 32588891 — intervention group
Group type: COMPARATOR
Intervention: Newsletter-only control group
Number of subjects: 605
Study 33586475 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthoses
Number of subjects: 81
Study 33586475 — intervention group
Group type: COMPARATOR
Intervention: None (Control)
Number of subjects: 81
Study 33310698 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy sessions (5 sessions, 2 weeks before the exam)
Number of subjects: 125
Study 33310698 — intervention group
Group type: COMPARATOR
Intervention: Control group (no music therapy)
Number of subjects: 125
Study 33493393 — intervention group
Group type: EXPERIMENTAL
Intervention: BSV (Besifovir dipivoxil maleate)
Number of subjects: 197
Study 33493393 — intervention group
Group type: COMPARATOR
Intervention: TDF (Tenofovir disoproxil fumarate) to BSV (Besifovir dipivoxil maleate) switch
Number of subjects: 197
Study 32448177 — intervention group
Group type: EXPERIMENTAL
Intervention: Single goal (SG) high dietary fiber intervention (≥30 g/day) with snacks containing 10‐12 g of dietary fiber for the first 6 weeks
Number of subjects: 12
Study 32448177 — intervention group
Group type: COMPARATOR
Intervention: Standard care (UC) group
Number of subjects: 12
Study 32448177 — intervention group
Group type: EXPERIMENTAL
Intervention: Single goal (SG) high dietary fiber intervention
Number of subjects: 12
Study 35119492 — intervention group
Group type: EXPERIMENTAL
Intervention: Friedman placement (baseplate peg placed perpendicular to the Friedman axis)
Number of subjects: 44
Study 35119492 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenoid placement (baseplate peg placed parallel to the glenoid surface)
Number of subjects: 44
Study 35119492 — intervention group
Group type: COMPARATOR
Intervention: Comparison between sexes
Number of subjects: 44
Study 33086239 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (0.08 mg/kg)
Number of subjects: 191
Study 33086239 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 191
Study 35840305 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT-I + ER intervention through self-guided online platform and four videoconferencing therapy sessions
Number of subjects: 156
Study 35840305 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT-I + ER intervention
Number of subjects: 156
Study 35840305 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 156
Study 33526026 — intervention group
Group type: EXPERIMENTAL
Intervention: JOBS Program Germany (intervention group)
Number of subjects: 1500
Study 33526026 — intervention group
Group type: COMPARATOR
Intervention: Waiting control group (control)
Number of subjects: 1500
Study 32780946 — intervention group
Group type: EXPERIMENTAL
Intervention: AS04-HPV-16/18 vaccine
Number of subjects: 227
Study 35977807 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 4304
Study 35977807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4304
Study 34338136 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 miRNA signature
Number of subjects: 514
Study 34338136 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNAs-based model
Number of subjects: 514
Study 34338136 — intervention group
Group type: EXPERIMENTAL
Intervention: miRNAs expression in EC tissues
Number of subjects: 514
Study 34059692 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I particle implantation therapy
Number of subjects: 62
Study 34059692 — intervention group
Group type: COMPARATOR
Intervention: Whole-pelvic irradiation and cisplatin-based concurrent chemoradiation therapy (Control)
Number of subjects: 62
Study 33378478 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation (MOP) with passive self-ligating brackets
Number of subjects: 60
Study 33378478 — intervention group
Group type: COMPARATOR
Intervention: Micro-osteoperforation (MOP) with conventional brackets
Number of subjects: 60
Study 33461308 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 4456
Study 33461308 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 4456
Study 33461308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4456
Study 33461308 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K Antagonists (VKA)
Number of subjects: 4456
Study 35344089 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard position (300 µm pre- and post-anterior capsule)
Number of subjects: 113
Study 35344089 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased distance (400 µm pre- and post-anterior capsule)
Number of subjects: 113
Study 35344089 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsymmetrical distances (200 µm pre- and 400 µm post-anterior capsule)
Number of subjects: 113
Study 34600245 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 40 mg
Number of subjects: 107
Study 34600245 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg
Number of subjects: 107
Study 34600245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 36320025 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive music intervention (60 min per day)
Number of subjects: 44
Study 34537339 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot interscalene nerve block (ISB)
Number of subjects: 77
Study 34537339 — intervention group
Group type: COMPARATOR
Intervention: Periarticular injection (PAI)
Number of subjects: 77
Study 35165387 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-infection plasma cytokine expression
Number of subjects: 69
Study 33143755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + placebo
Number of subjects: 439
Study 33143755 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics + placebo
Number of subjects: 439
Study 33143755 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil + probiotics
Number of subjects: 439
Study 33143755 — intervention group
Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 439
Study 33143755 — intervention group
Group type: EXPERIMENTAL
Intervention: GDM (gestational diabetes)
Number of subjects: 439
Study 32907904 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of 10 mg elobixibat (EXB) and 9 g cholestyramine (CTM) powder
Number of subjects: 100
Study 32907904 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg elobixibat (EXB) monotherapy
Number of subjects: 100
Study 32907904 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 g cholestyramine (CTM) powder monotherapy
Number of subjects: 100
Study 32907904 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study 34009888 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app CDST
Number of subjects: 149
Study 34009888 — intervention group
Group type: EXPERIMENTAL
Intervention: Print CDST
Number of subjects: 149
Study 34009888 — intervention group
Group type: COMPARATOR
Intervention: No CDST
Number of subjects: 149
Study 33002927 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical + TOF monitoring
Number of subjects: 77
Study 33002927 — intervention group
Group type: COMPARATOR
Intervention: Clinical monitoring
Number of subjects: 77
Study 35631137 — intervention group
Group type: EXPERIMENTAL
Intervention: LOW‐HIIT (14 min/session, 2 ×/week for 12 weeks)
Number of subjects: 106
Study 35631137 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐RT (50 min/session, 2 ×/week for 12 weeks)
Number of subjects: 106
Study 35631137 — intervention group
Group type: EXPERIMENTAL
Intervention: 1‐RT (15 min/session, 2 ×/week for 12 weeks)
Number of subjects: 106
Study 33739852 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensified pegaspargase (four additional doses at 3-week intervals during consolidation and interim maintenance)
Number of subjects: 1857
Study 33739852 — intervention group
Group type: COMPARATOR
Intervention: Standard COG low-intensity therapy (including two pegaspargase doses during induction and delayed intensification)
Number of subjects: 1857
Study 33739852 — intervention group
Group type: COMPARATOR
Intervention: Low-risk patients compared to standard-risk patients with identical therapy
Number of subjects: 1857
Study 33739852 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS) for intensified pegaspargase
Number of subjects: 1857
Study 33739852 — intervention group
Group type: COMPARATOR
Intervention: Overall survival (OS) for standard COG therapy
Number of subjects: 1857
Study 33031335 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT) intervention for 12 weeks
Number of subjects: 68
Study 33031335 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention group (control)
Number of subjects: 68
Study 35506299 — intervention group
Group type: EXPERIMENTAL
Intervention: Freeze-dried bone allograft (FDBA) combined with collagen membrane
Number of subjects: 48
Study 35506299 — intervention group
Group type: COMPARATOR
Intervention: Autogenous bone chips plus deproteinized bovine bone material (DBBM)
Number of subjects: 48
Study 35506299 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (FDBA and DBBM)
Number of subjects: 48
Study 32921069 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive metastasis-directed therapy (MDT) with surgery and/or hypofractionated image-guided radiation therapy (HIGRT)
Number of subjects: 0
Study 32921069 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT for oligometastatic breast cancer
Number of subjects: 0
Study 32921069 — intervention group
Group type: EXPERIMENTAL
Intervention: MDT
Number of subjects: 0
Study 32921069 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved systemic therapies (targeted agents and immunotherapy)
Number of subjects: 0